CONNECT BIOPHARMA HOLDINGS L (CNTB)
US2075231017 - ADR
Taking everything into account, CNTB scores 2 out of 10 in our fundamental rating. CNTB was compared to 587 industry peers in the Biotechnology industry. The financial health of CNTB is average, but there are quite some concerns on its profitability. CNTB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CNTB has reported negative net income.
In the past year CNTB has reported a negative cash flow from operations.
CNTB had negative earnings in each of the past 5 years.
In the past 5 years CNTB always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of CNTB (-70.51%) is worse than 65.30% of its industry peers.
With a Return On Equity value of -87.85%, CNTB perfoms like the industry average, outperforming 49.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.51% | ||
| ROE | -87.85% | ||
| ROIC | N/A |
ROA(3y)-61.15%
ROA(5y)-60.11%
ROE(3y)-68.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CNTB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for CNTB remains at a similar level compared to 1 year ago.
CNTB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CNTB has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 10.09 indicates that CNTB is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.09, CNTB belongs to the top of the industry, outperforming 86.32% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that CNTB is not too dependend on debt financing.
CNTB has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: CNTB outperforms 48.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.09 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNTB has a Current Ratio of 4.99. This indicates that CNTB is financially healthy and has no problem in meeting its short term obligations.
CNTB has a Current ratio (4.99) which is in line with its industry peers.
CNTB has a Quick Ratio of 4.99. This indicates that CNTB is financially healthy and has no problem in meeting its short term obligations.
CNTB has a Quick ratio of 4.99. This is comparable to the rest of the industry: CNTB outperforms 54.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.99 | ||
| Quick Ratio | 4.99 |
3. Growth
3.1 Past
CNTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.21%, which is quite impressive.
EPS 1Y (TTM)92.21%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2QN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, CNTB will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.53% on average per year.
The Revenue is expected to grow by 22.15% on average over the next years. This is a very strong growth
EPS Next Y34.12%
EPS Next 2Y3.65%
EPS Next 3Y-18.2%
EPS Next 5Y12.53%
Revenue Next Year305.78%
Revenue Next 2Y30.24%
Revenue Next 3Y-36.52%
Revenue Next 5Y22.15%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CNTB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CNTB's earnings are expected to decrease with -18.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.65%
EPS Next 3Y-18.2%
5. Dividend
5.1 Amount
CNTB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CONNECT BIOPHARMA HOLDINGS L
NASDAQ:CNTB (5/16/2024, 7:00:00 PM)
1.72
-0.1 (-5.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap94.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.51% | ||
| ROE | -87.85% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.99 | ||
| Quick Ratio | 4.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)92.21%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y34.12%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y